InvestorsHub Logo
Followers 54
Posts 3476
Boards Moderated 0
Alias Born 10/26/2013

Re: Ville post# 2187

Thursday, 05/17/2018 7:14:55 AM

Thursday, May 17, 2018 7:14:55 AM

Post# of 3283
They corrected the PR regarding Rolontis patient number.

CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
Business Wire Business Wire•May 17, 2018
HENDERSON, Nev.--(BUSINESS WIRE)--

Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”).